Zybrestat fosbretabulin: Phase II data

OxiGene reported data from the double-blind, placebo-controlled, Asian Phase II FAVOR trial in 20 patients with PCV showing that a single IV injection of Zybrestat led to "essentially" no change in the number of polyps from baseline, the primary endpoint. Zybrestat was well tolerated. Patients received a single IV injection of Zybrestat or placebo followed by imaging of the retina on days 2, 8, 15 and 28. Data were presented at the Asia-Pacific VitreoRetina Society meeting in Hyderabad. Next steps were not disclosed. ...